These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 23494609

  • 1. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
    Chang AM, Ho JC, Yan BP, Yu CM, Lam YY, Lee VW.
    Clin Cardiol; 2013 May; 36(5):280-5. PubMed ID: 23494609
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J, Delaitre O, Hammès F, de Pouvourville G.
    Arch Cardiovasc Dis; 2014 May; 107(6-7):381-90. PubMed ID: 24973113
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H, Johnston SC, Easton JD, Kim AS.
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV, Gage BF.
    Circulation; 2011 Jun 07; 123(22):2562-70. PubMed ID: 21606397
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
    Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y.
    Cardiovasc Drugs Ther; 2014 Dec 07; 28(6):575-85. PubMed ID: 25319314
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.
    Ann Intern Med; 2011 Jan 04; 154(1):1-11. PubMed ID: 21041570
    [Abstract] [Full Text] [Related]

  • 7. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
    Bergh M, Marais CA, Miller-Jansön H, Salie F, Stander MP.
    S Afr Med J; 2013 Feb 15; 103(4):241-5. PubMed ID: 23547700
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    Davidson T, Husberg M, Janzon M, Oldgren J, Levin LÅ.
    Eur Heart J; 2013 Jan 15; 34(3):177-83. PubMed ID: 22733833
    [Abstract] [Full Text] [Related]

  • 9. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Edwards DB, Silverberg J.
    Ann Intern Med; 2011 Apr 19; 154(8):570; author reply 570-1. PubMed ID: 21502658
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
    González-Juanatey JR, Álvarez-Sabin J, Lobos JM, Martínez-Rubio A, Reverter JC, Oyagüez I, González-Rojas N, Becerra V.
    Rev Esp Cardiol (Engl Ed); 2012 Oct 19; 65(10):901-10. PubMed ID: 22958943
    [Abstract] [Full Text] [Related]

  • 11. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
    Adcock AK, Lee-Iannotti JK, Aguilar MI, Hoffman-Snyder CR, Wingerchuk DM, Wellik KE, Demaerschalk BM.
    Neurologist; 2012 Mar 19; 18(2):102-7. PubMed ID: 22367842
    [Abstract] [Full Text] [Related]

  • 12. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
    Singh SM, Micieli A, Wijeysundera HC.
    Circulation; 2013 Jun 18; 127(24):2414-23. PubMed ID: 23697908
    [Abstract] [Full Text] [Related]

  • 13. Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
    Ho JC, Chang AM, Yan BP, Yu CM, Lam YY, Lee VW.
    Clin Cardiol; 2012 Dec 18; 35(12):E40-5. PubMed ID: 23108916
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.
    Value Health; 2013 Jun 18; 16(4):498-506. PubMed ID: 23796283
    [Abstract] [Full Text] [Related]

  • 15. A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
    Sorensen SV, Peng S, Monz BU, Bradley-Kennedy C, Kansal AR.
    Pharmacoeconomics; 2013 Jul 18; 31(7):589-604. PubMed ID: 23615895
    [Abstract] [Full Text] [Related]

  • 16. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.
    J Med Econ; 2013 Sep 18; 16(9):1163-8. PubMed ID: 23869941
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
    You JH, Tsui KK, Wong RS, Cheng G.
    PLoS One; 2012 Sep 18; 7(6):e39640. PubMed ID: 22745801
    [Abstract] [Full Text] [Related]

  • 18. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A, Bailey C, Abdelhafiz AH.
    Age Ageing; 2012 Sep 18; 41(5):681-4. PubMed ID: 22378612
    [Abstract] [Full Text] [Related]

  • 19. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.
    J Med Econ; 2014 Aug 18; 17(8):587-98. PubMed ID: 24831811
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington AR, Armstrong EP, Nolan PE, Malone DC.
    Stroke; 2013 Jun 18; 44(6):1676-81. PubMed ID: 23549134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.